J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius
The deal sets the biosimilar’s potential US launch date to no later than April 2025, following two agreements signed earlier this year.
The deal sets the biosimilar’s potential US launch date to no later than April 2025, following two agreements signed earlier this year.
What's Your Reaction?
